Home › KEYTRUDA (pembrolizumab) from Merck Awarded Prix Galien USA 2015 Best Biotechnology Product Award
 

Keywords :   


KEYTRUDA (pembrolizumab) from Merck Awarded Prix Galien USA 2015 Best Biotechnology Product Award

2015-10-28 13:00:00| Merck.com - Corporate News

Dateline City: KENILWORTH, N.J. KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that KEYTRUDA (pembrolizumab), the companys anti-PD-1 therapy for the treatment of advanced melanoma and metastatic non-small cell lung cancer in patients whose disease has progressed after other therapies, received the Prix Galien USA 2015 Award for Best Biotechnology Product. Language: English Contact: Media:Pamela Eisele, 267-305-3558 Ticker Slug: Ticker: MRK Exchange: NYSE read more

Tags: product usa prix award

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news
»
03.07Hurricane Beryl Graphics
03.07Atlantic Tropical Weather Outlook
03.07Hurricane Beryl Public Advisory Number 17A
03.07Summary for Hurricane Beryl (AT2/AL022024)
03.07Eastern North Pacific Tropical Weather Outlook
03.07How Microsoft and Nvidia bet correctly to leapfrog Apple
03.07Acreage and stocks estimates push corn prices lower
03.07Lakamps research aims to use cattle genetics and microbiome information to make performance predictions
More »